Jieyun Yin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Jieyun Yin has a total of 107 co-authors. Here are the top co-authors by number of shared publications:
- Erica Ollmann Saphire
Center for Vaccine Innovation, La Jolla Institute for Immunology, La Jolla, USA
3 shared publications - Kathryn M. Hastie
Center for Vaccine Innovation, La Jolla Institute for Immunology, La Jolla, CA 92037, USA
3 shared publications - Sharon L. Schendel
La Jolla Institute for Immunology
3 shared publications - Adrian S. Enriquez
Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, 9420 Athena Circle, La Jolla, CA 92037, USA
2 shared publications - Dawid S. Zyla
Center for Vaccine Innovation, La Jolla Institute for Immunology, La Jolla, USA
2 shared publications - Diptiben Parekh
Center for Vaccine Innovation, La Jolla Institute for Immunology, La Jolla, CA 92037, USA
2 shared publications
Latest Publications
- 26 October 2022
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 14 (668) , eabq0991
A cocktail of protective antibodies subverts the dense glycan shield of Lassa virus
Developing potent therapeutics and effective vaccines are the ultimate goals in controlling infectious diseases. Lassa virus (LASV), the causative pathogen of Lassa fever (LF), infects hundreds of thousands annually, but effective antivirals or vaccines against LASV infection are still lacking. Furthermore, neutralizing antibodies against LASV are rare. Here, we describe biochemical analyses and high-resolution cryo-electron microscopy structures of a therapeutic cocktail of three broadly protective antibodies that target the LASV glycoprotein complex (GPC), previously identified from survivors of multiple LASV infections. Structural and mechanistic analyses reveal compatible neutralizing epitopes and complementary neutralization mechanisms that offer high potency, broad range, and resistance to escape. These antibodies either circumvent or exploit specific glycans comprising the extensive glycan shield of GPC. Further, they require mammalian glycosylation, native GPC cleavage, and proper GPC trimerization. These findings guided engineering of a next-generation GPC antigen suitable for future neutralizing antibody and vaccine discovery. Together, these results explain protective mechanisms of rare, broad, and potent antibodies and identify a strategy for the rational design of therapeutic modalities against LF and related infectious diseases.
- 26 October 2022
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 14 (668) , eabq0991
A cocktail of protective antibodies subverts the dense glycan shield of Lassa virus
Developing potent therapeutics and effective vaccines are the ultimate goals in controlling infectious diseases. Lassa virus (LASV), the causative pathogen of Lassa fever (LF), infects hundreds of thousands annually, but effective antivirals or vaccines against LASV infection are still lacking. Furthermore, neutralizing antibodies against LASV are rare. Here, we describe biochemical analyses and high-resolution cryo-electron microscopy structures of a therapeutic cocktail of three broadly protective antibodies that target the LASV glycoprotein complex (GPC), previously identified from survivors of multiple LASV infections. Structural and mechanistic analyses reveal compatible neutralizing epitopes and complementary neutralization mechanisms that offer high potency, broad range, and resistance to escape. These antibodies either circumvent or exploit specific glycans comprising the extensive glycan shield of GPC. Further, they require mammalian glycosylation, native GPC cleavage, and proper GPC trimerization. These findings guided engineering of a next-generation GPC antigen suitable for future neutralizing antibody and vaccine discovery. Together, these results explain protective mechanisms of rare, broad, and potent antibodies and identify a strategy for the rational design of therapeutic modalities against LF and related infectious diseases.
- Open Access
- 22 July 2022
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 8 (29) , eabn1440
Measles and Nipah virus assembly: Specific lipid binding drives matrix polymerization
Measles virus, Nipah virus, and multiple other paramyxoviruses cause disease outbreaks in humans and animals worldwide. The paramyxovirus matrix (M) protein mediates virion assembly and budding from host cell membranes. M is thus a key target for antivirals, but few high-resolution structures of paramyxovirus M are available, and we lack the clear understanding of how viral M proteins interact with membrane lipids to mediate viral assembly and egress that is needed to guide antiviral design. Here, we reveal that M proteins associate with phosphatidylserine and phosphatidylinositol 4,5-bisphosphate [PI(4,5)P 2 ] at the plasma membrane. Using x-ray crystallography, electron microscopy, and molecular dynamics, we demonstrate that PI(4,5)P 2 binding induces conformational and electrostatic changes in the M protein surface that trigger membrane deformation, matrix layer polymerization, and virion assembly.
- 22 July 2022
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 8 (29) , eabn1440
Open AccessMeasles and Nipah virus assembly: Specific lipid binding drives matrix polymerization
Measles virus, Nipah virus, and multiple other paramyxoviruses cause disease outbreaks in humans and animals worldwide. The paramyxovirus matrix (M) protein mediates virion assembly and budding from host cell membranes. M is thus a key target for antivirals, but few high-resolution structures of paramyxovirus M are available, and we lack the clear understanding of how viral M proteins interact with membrane lipids to mediate viral assembly and egress that is needed to guide antiviral design. Here, we reveal that M proteins associate with phosphatidylserine and phosphatidylinositol 4,5-bisphosphate [PI(4,5)P 2 ] at the plasma membrane. Using x-ray crystallography, electron microscopy, and molecular dynamics, we demonstrate that PI(4,5)P 2 binding induces conformational and electrostatic changes in the M protein surface that trigger membrane deformation, matrix layer polymerization, and virion assembly.
- Top Cited PapersOpen Access
- 23 September 2021
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 374 (6566) , 472-478
Defining variant-resistant epitopes targeted by SARS-CoV-2 antibodies: A global consortium study
Community of antibodies against COVID-19: The severe acute respiratory syndrome coronavirus 2 spike protein is the basis of many vaccines and is a primary target of neutralizing antibodies after COVID-19 infection. The Coronavirus Immunotherapeutic Consortium (CoVIC), comprising 56 partners across the world, has analyzed a panel of 269 monoclonal antibodies (mAbs) and, on the basis of competition profiles, sorted 186 mAbs that target the receptor binding domain into seven communities. Hastie et al . went on to structurally analyze representative antibody binding and used pseudovirus neutralization assays to study the effect of spike mutations on antibody function, including the combinations of mutations found in certain variants of concern. These results are important to guide both treatment and prevention efforts. —VV
- 23 September 2021
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 374 (6566) , 472-478
Top Cited PapersOpen AccessDefining variant-resistant epitopes targeted by SARS-CoV-2 antibodies: A global consortium study
Community of antibodies against COVID-19: The severe acute respiratory syndrome coronavirus 2 spike protein is the basis of many vaccines and is a primary target of neutralizing antibodies after COVID-19 infection. The Coronavirus Immunotherapeutic Consortium (CoVIC), comprising 56 partners across the world, has analyzed a panel of 269 monoclonal antibodies (mAbs) and, on the basis of competition profiles, sorted 186 mAbs that target the receptor binding domain into seven communities. Hastie et al . went on to structurally analyze representative antibody binding and used pseudovirus neutralization assays to study the effect of spike mutations on antibody function, including the combinations of mutations found in certain variants of concern. These results are important to guide both treatment and prevention efforts. —VV
- Open Access
- 2 March 2017
- Published by Impact Journals, LLC in Oncotarget
- Vol. 8 (16) , 26871-26885
A novel oncolytic adenovirus based on simian adenovirus serotype 24
A novel oncolytic adenovirus based on simian adenovirus serotype 24 A novel oncolytic adenovirus based on simian adenovirus serotype 24
- 2 March 2017
- Published by Impact Journals, LLC in Oncotarget
- Vol. 8 (16) , 26871-26885
Open AccessA novel oncolytic adenovirus based on simian adenovirus serotype 24
A novel oncolytic adenovirus based on simian adenovirus serotype 24 A novel oncolytic adenovirus based on simian adenovirus serotype 24